March 7, 2019 06:29 AM EST
Financing
Pharma

At­ul Gawande takes aim at surg­ing pre­scrip­tion drug costs as chief of cryp­tic Buf­fett-Be­zos-Di­mon ven­ture now chris­tened 'Haven'

Natalie Grover

Reporter

Ear­ly last year, when the pow­er­ful trio of War­ren Buf­fett (Berk­shire Hath­away), Jamie Di­mon (JP­Mor­gan Chase) and Jeff Be­zos (Ama­zon) joined forces to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times